tiprankstipranks
Trending News
More News >
AstraZeneca PLC (GB:AZN)
LSE:AZN
Advertisement

AstraZeneca (AZN) AI Stock Analysis

Compare
738 Followers

Top Page

GB:AZN

AstraZeneca

(LSE:AZN)

Rating:78Outperform
Price Target:
12,780.00p
▲(17.01% Upside)
AstraZeneca's strong financial performance and strategic investments in R&D and manufacturing are significant strengths. Positive technical indicators and robust earnings call insights further support the stock's potential. However, high valuation metrics and cash flow management challenges slightly temper the overall score.
Positive Factors
Clinical Trials
Baxdrostat demonstrated a 'statistically significant' and 'clinically meaningful' lowering in systolic blood pressure, meeting all secondary endpoints.
Financial Performance
AstraZeneca's FX outlook has improved, potentially leading to revenue and EPS upgrades.
Product Sales
Non-oncology accounts for 51% of group Product Sales CAGR of 6% and all the upside projected to the consensus estimates, highlighting its importance in AstraZeneca's growth prospects.
Negative Factors
Drug Development Risks
Main downsides to the 2031 group EBITA include potential growth issues with the Enhertu drug and the removal of Datroway from the model.
Market Challenges
Assuming low penetration due to difficulty in predicting market adoption in a heavily genericised market.
Policy and Cost Pressures
US policy debates and higher R&D spending may limit the scope for guidance upgrades.

AstraZeneca (AZN) vs. iShares MSCI United Kingdom ETF (EWC)

AstraZeneca Business Overview & Revenue Model

Company DescriptionAstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
How the Company Makes MoneyAstraZeneca generates revenue primarily through the sale of its prescription medicines. The company's revenue model is centered around developing innovative drugs and securing regulatory approval for their commercial distribution. Key revenue streams include sales of branded pharmaceuticals in therapeutic areas such as oncology, where AstraZeneca has a strong portfolio of cancer treatments, and cardiovascular, renal & metabolism, which includes drugs for diabetes and heart-related conditions. Additionally, AstraZeneca engages in strategic partnerships and collaborations with other pharmaceutical companies and research institutions to enhance its research and development capabilities. The company also benefits from patent protections, which provide exclusivity for its products and allow for premium pricing. AstraZeneca's earnings are influenced by factors such as drug pricing regulations, competition from generic drugs, and the success of its new drug launches.

AstraZeneca Earnings Call Summary

Earnings Call Date:Jul 29, 2025
(Q2-2025)
|
% Change Since: 1.93%|
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted AstraZeneca's strong revenue and EPS growth driven by demand for innovative medicines and a successful pipeline. However, challenges remain in specific markets like China and anticipated margin declines. The sentiment is balanced by the company's robust performance in oncology and biopharmaceuticals, alongside pipeline successes.
Q2-2025 Updates
Positive Updates
Strong Revenue and EPS Growth
Total revenue grew by 11% in the first half of 2025, driven by demand for innovative medicines. Core EPS grew 17%, reflecting investment in the pipeline and operational leverage.
Pipeline and Regulatory Success
AstraZeneca achieved 19 regulatory approvals in key regions and announced results of 12 positive Phase III trials, including pivotal data for 5 new molecular entities.
Oncology Segment Performance
Oncology revenue grew 16% to $12 billion in the first half, with notable growth in key brands like Tagrisso (12% growth) and Enhertu (42% growth in Q2).
Emerging Market Growth
Strong performance in emerging markets outside of China, contributing to robust geographical growth.
Biopharmaceuticals and Rare Disease Momentum
Biopharmaceuticals delivered 10% growth to $11.2 billion, with rare disease returning to growth in Q2, up 7%.
Negative Updates
China's Challenging Market
Growth in China continues to be affected by Pulmicort generics, impacting revenue growth in the region.
Gross Margin Decline Anticipation
Total revenue core gross margin is expected to decline by around 60 to 70 basis points in 2025 due to factors like Medicare Part D redesign and Soliris biosimilar competition.
Anselamimab Trial Disappointment
Phase III CARES program for anselamimab in severe light-chain amyloidosis did not achieve statistical significance for the primary endpoint in the overall patient population.
Company Guidance
In the recent call, AstraZeneca provided guidance for the first half of 2025, reporting an 11% growth in total revenue, primarily driven by the demand for innovative medicines. Core EPS saw a 17% increase, reflecting strategic investments in their pipeline. The company achieved 19 regulatory approvals in key regions, with 12 positive Phase III trials announced, including five new molecular entities. Specific growth was noted in oncology and biopharmaceuticals, with rare diseases showing a 7% increase in the second quarter. The KALOS/LOGOS program and BaxHTN trial are highlighted as significant contributors to future growth. AstraZeneca maintains its 2030 ambition, aiming for $80 billion in revenue, with transformative technologies expected to drive growth beyond this target. The company also reiterated its guidance for the year, anticipating high single-digit revenue growth and low double-digit EPS growth.

AstraZeneca Financial Statement Overview

Summary
AstraZeneca exhibits strong financial health with consistent revenue growth, high profitability margins, and a balanced capital structure. However, there are some challenges in cash flow management, as indicated by a decline in free cash flow growth.
Income Statement
85
Very Positive
AstraZeneca demonstrates strong profitability with a consistent gross profit margin above 80% and a healthy net profit margin of 14.68% in TTM. Revenue growth is steady at 2.76% TTM, indicating a stable upward trajectory. The EBIT and EBITDA margins are robust, reflecting efficient operations and cost management.
Balance Sheet
78
Positive
The company's debt-to-equity ratio of 0.73 indicates a balanced capital structure, with manageable leverage. Return on equity is strong at 19.84%, showcasing effective use of shareholder funds. The equity ratio is solid, suggesting a stable financial position with adequate asset backing.
Cash Flow
70
Positive
Operating cash flow is strong, but free cash flow growth has declined by 9.86% TTM, which could indicate potential cash flow management challenges. The operating cash flow to net income ratio is healthy, but there is room for improvement in free cash flow conversion.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue57.30B54.07B45.81B44.35B37.42B26.62B
Gross Profit41.60B43.87B37.77B31.96B24.98B21.32B
EBITDA18.84B15.44B13.91B9.09B5.11B8.08B
Net Income8.45B7.04B5.96B3.29B112.00M3.20B
Balance Sheet
Total Assets112.42B104.03B101.12B96.48B105.36B66.73B
Cash, Cash Equivalents and Short-Term Investments7.11B5.53B5.86B6.41B6.40B7.99B
Total Debt32.84B30.11B28.62B29.23B30.78B20.38B
Total Liabilities67.61B63.16B61.95B59.42B66.08B51.09B
Stockholders Equity44.72B40.79B39.14B37.04B39.27B15.62B
Cash Flow
Free Cash Flow8.72B7.28B6.57B7.24B3.76B2.19B
Operating Cash Flow13.39B11.86B10.35B9.81B5.96B4.80B
Investing Cash Flow-6.06B-7.98B-4.06B-2.96B-11.06B-285.00M
Financing Cash Flow-6.99B-4.00B-6.57B-6.82B3.65B-2.20B

AstraZeneca Technical Analysis

Technical Analysis Sentiment
Positive
Last Price10922.00
Price Trends
50DMA
10571.91
Positive
100DMA
10568.95
Positive
200DMA
10678.06
Positive
Market Momentum
MACD
170.74
Negative
RSI
55.11
Neutral
STOCH
27.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AZN, the sentiment is Positive. The current price of 10922 is above the 20-day moving average (MA) of 10748.64, above the 50-day MA of 10571.91, and above the 200-day MA of 10678.06, indicating a bullish trend. The MACD of 170.74 indicates Negative momentum. The RSI at 55.11 is Neutral, neither overbought nor oversold. The STOCH value of 27.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:AZN.

AstraZeneca Risk Analysis

AstraZeneca disclosed 19 risk factors in its most recent earnings report. AstraZeneca reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

AstraZeneca Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
£171.36B26.6920.09%1.74%11.89%25.68%
76
Outperform
£11.70B30.809.30%2.37%2.51%56.56%
75
Outperform
£55.39B16.3523.47%4.17%0.59%-15.36%
71
Outperform
£4.15B14.5415.66%3.54%3.73%27.13%
51
Neutral
$7.38B-0.04-62.85%2.34%15.18%-2.87%
$52.69B4.5213.12%7.53%
67
Neutral
£31.26B20.719.35%1.52%-2.12%42.10%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:AZN
AstraZeneca
10,922.00
-1,508.85
-12.14%
GB:GSK
GlaxoSmithKline
1,395.50
-103.31
-6.89%
GB:HIK
Hikma Pharmaceuticals
1,740.00
-237.88
-12.03%
GB:SN
Smith & Nephew
1,340.50
204.10
17.96%
GB:BXP
Beximco Pharmaceuticals Limited Sponsored GDR RegS
44.50
10.75
31.85%
GB:HLN
Haleon PLC
355.20
-15.25
-4.12%

AstraZeneca Corporate Events

Regulatory Filings and Compliance
AstraZeneca Announces Updated Share Capital and Voting Rights
Neutral
Aug 1, 2025

AstraZeneca PLC has announced that as of July 31, 2025, its issued share capital with voting rights consists of 1,550,682,580 ordinary shares, with no shares held in Treasury. This figure is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules, potentially impacting their interest calculations in the company.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £165.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
AstraZeneca Reports Strong H1 2025 Results and Announces Major US Investment
Positive
Jul 29, 2025

AstraZeneca reported strong financial results for the first half of 2025, with a significant increase in total revenue driven by growth in oncology and biopharmaceuticals. The company announced a $50 billion investment in US manufacturing and R&D, including the largest manufacturing facility in its history, to support its ambitious growth plans. This investment highlights AstraZeneca’s confidence in its innovative medicines and its commitment to achieving $80 billion in revenue by 2030. The company also reported several positive Phase III trial outcomes and regulatory approvals, reinforcing its strong position in the pharmaceutical industry.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Product-Related Announcements
AstraZeneca’s Gefurulimab Shows Promise in Phase III Trial for Myasthenia Gravis
Positive
Jul 24, 2025

AstraZeneca announced positive results from the Phase III PREVAIL trial for gefurulimab, a novel C5 inhibitor for generalized myasthenia gravis (gMG). The trial demonstrated significant improvements in daily living activities and disease severity, positioning gefurulimab as a promising self-administered treatment option, potentially enhancing patient independence and disease management.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Business Operations and Strategy
AstraZeneca Announces $50 Billion Investment in US Manufacturing and R&D
Positive
Jul 22, 2025

AstraZeneca has announced a $50 billion investment in the United States by 2030, aimed at enhancing its medicines manufacturing and R&D capabilities. This investment, which includes the establishment of a new drug substance manufacturing center in Virginia, is expected to create tens of thousands of jobs and support AstraZeneca’s goal of reaching $80 billion in revenue by 2030, with 50% of it generated in the US. The initiative underscores AstraZeneca’s commitment to strengthening the domestic supply chain and advancing pharmaceutical manufacturing technology.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
AstraZeneca’s Anselamimab Shows Promise in Subgroup of Amyloidosis Patients
Neutral
Jul 16, 2025

AstraZeneca’s CARES Phase III clinical program for anselamimab in light chain amyloidosis did not achieve statistical significance for the primary endpoint in the overall patient population. However, anselamimab showed clinically meaningful improvements in survival and cardiovascular hospitalization in a prespecified subgroup of patients, indicating potential to address a critical treatment gap. The investigational drug was well tolerated, and further evaluation is ongoing to assess its efficacy and safety, with plans to share data with global health authorities.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
AstraZeneca’s Baxdrostat Shows Promising Results in Hypertension Trial
Positive
Jul 14, 2025

AstraZeneca announced positive results from its BaxHTN Phase III trial, where its drug Baxdrostat significantly reduced systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension. This breakthrough offers a potential new treatment approach targeting aldosterone dysregulation, addressing a critical unmet need in hypertension management and potentially enhancing AstraZeneca’s position in the cardiovascular market.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Product-Related Announcements
AstraZeneca’s Imfinzi Gains EU Approval for Bladder Cancer Treatment
Positive
Jul 4, 2025

AstraZeneca’s Imfinzi has been approved by the European Union as the first perioperative immunotherapy for muscle-invasive bladder cancer, based on the NIAGARA Phase III trial results. This approval is expected to transform the standard of care in Europe, offering a significant reduction in disease recurrence and extending survival rates, thereby setting a new benchmark for treatment in this area.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Regulatory Filings and Compliance
AstraZeneca Announces Updated Share Capital and Voting Rights
Neutral
Jul 1, 2025

AstraZeneca PLC has announced that as of 30 June 2025, its issued share capital with voting rights totals 1,550,670,668 ordinary shares, with no shares held in Treasury. This figure is crucial for shareholders to calculate their interests in compliance with the UK Financial Conduct Authority’s Disclosure and Transparency Rules, impacting how stakeholders manage their shareholdings.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Product-Related Announcements
AstraZeneca’s Datroway Gains US Approval for Advanced Lung Cancer Treatment
Positive
Jun 24, 2025

AstraZeneca, in collaboration with Daiichi Sankyo, has announced the accelerated approval of Datroway (datopotamab deruxtecan) in the US for the treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC) in patients who have previously undergone EGFR-directed therapy and platinum-based chemotherapy. This approval marks the first TROP2-directed therapy for lung cancer in the US, offering a new treatment option for patients with limited alternatives. The approval is based on promising results from the TROPION-Lung05 and TROPION-Lung01 trials, demonstrating a significant objective response rate and duration of response. The introduction of Datroway is expected to strengthen AstraZeneca’s position in the oncology market, providing a novel option for patients with advanced disease and potentially expanding its use in other cancer types.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Product-Related Announcements
AstraZeneca’s Calquence Regimen Approved in EU for Untreated CLL
Positive
Jun 6, 2025

AstraZeneca has received approval from the European Union for a fixed-duration regimen of its drug Calquence, in combination with venetoclax, with or without obinutuzumab, for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). This approval is based on positive results from the AMPLIFY Phase III trial, which demonstrated significant improvements in progression-free survival compared to standard chemoimmunotherapy. The approval provides a new all-oral treatment option that may help minimize long-term side effects and improve adherence, potentially impacting AstraZeneca’s market position in the oncology sector.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £190.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Regulatory Filings and Compliance
AstraZeneca Announces Share Capital and Voting Rights Update
Neutral
Jun 2, 2025

AstraZeneca has announced that as of 31 May 2025, its issued share capital with voting rights consists of 1,550,657,962 ordinary shares. This figure is significant for shareholders as it serves as the denominator for calculating their interests under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
AstraZeneca’s Imfinzi Gains EU Approval Recommendation for Bladder Cancer
Positive
May 27, 2025

AstraZeneca’s Imfinzi has been recommended for approval by the CHMP in the EU as the first perioperative immunotherapy for muscle-invasive bladder cancer. The recommendation is based on the NIAGARA Phase III trial, which showed significant reductions in disease recurrence and death risk compared to neoadjuvant chemotherapy alone. This approval could transform treatment approaches in Europe, offering a new standard of care for patients with resectable muscle-invasive bladder cancer.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Product-Related Announcements
AstraZeneca’s Imfinzi Gains EU Approval Recommendation for Bladder Cancer
Positive
May 27, 2025

AstraZeneca’s Imfinzi has been recommended for approval in the EU as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC), based on the NIAGARA Phase III trial results. The trial demonstrated significant reductions in the risk of disease progression and death, supporting Imfinzi’s potential to become a new standard of care in Europe, offering a much-needed treatment option for MIBC patients and potentially transforming the treatment landscape.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Executive/Board Changes
AstraZeneca CEO Receives Vested Shares Under Performance Plan
Neutral
May 23, 2025

AstraZeneca announced the vesting of ordinary shares to CEO Pascal Soriot under the AstraZeneca Performance Share Plan. The award, granted in 2020, vested after a three-year performance period and a two-year holding period, resulting in 97% of the award vesting. This transaction reflects AstraZeneca’s commitment to rewarding its leadership based on performance, potentially impacting the company’s executive compensation strategy and stakeholder perceptions.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £14500.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

M&A TransactionsBusiness Operations and Strategy
AstraZeneca Completes Acquisition of EsoBiotec to Enhance Cell Therapy Capabilities
Positive
May 20, 2025

AstraZeneca has completed the acquisition of EsoBiotec, a biotechnology company known for its innovative in vivo cell therapies, particularly the Engineered NanoBody Lentiviral (ENaBL) platform. This acquisition, valued at up to $1 billion, positions AstraZeneca to enhance its cell therapy capabilities, potentially transforming cancer treatment by enabling quicker and more accessible therapies. The acquisition aligns with AstraZeneca’s strategic focus on oncology and immune-mediated diseases, aiming to redefine cancer care and address unmet needs in chronic diseases.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
AstraZeneca’s Imfinzi Shows Promise in Bladder Cancer Trial
Positive
May 9, 2025

AstraZeneca announced positive results from its POTOMAC Phase III trial, where the Imfinzi regimen showed a significant improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer. This advancement could potentially enhance treatment options for early-stage bladder cancer, aligning with AstraZeneca’s strategy to bring novel therapies to patients where long-term benefits are most achievable. The safety profile of Imfinzi combined with BCG therapy was consistent with known profiles, and no new safety concerns were identified. These findings will be shared with global regulatory authorities, potentially impacting AstraZeneca’s market positioning and offering new hope for stakeholders involved in bladder cancer treatment.

Product-Related AnnouncementsBusiness Operations and Strategy
AstraZeneca’s Enhertu Shows Promise in Early-Stage Breast Cancer Trial
Positive
May 7, 2025

AstraZeneca and Daiichi Sankyo announced positive results from the DESTINY-Breast11 Phase III trial, showing that Enhertu followed by THP significantly improves pathologic complete response rates in high-risk HER2-positive early-stage breast cancer patients compared to the standard of care. This trial marks the first Phase III success for Enhertu in early breast cancer and suggests a potential shift in treatment paradigms, offering a promising new approach that could improve patient outcomes and challenge existing standards.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 06, 2025